Technical Analysis for ACST - Acasti Pharma, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical ACST trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 19 | MACD Bullish Signal Line Cross | Bullish | 0.00% |
| Mar 19 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Mar 19 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Mar 19 | NR7 | Range Contraction | 0.00% |
| Mar 18 | MACD Bearish Signal Line Cross | Bearish | 0.94% |
| Mar 18 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.94% |
| Mar 18 | Bollinger Band Squeeze | Range Contraction | 0.94% |
| Mar 18 | BB Squeeze Started | Range Contraction | 0.94% |
| Mar 15 | MACD Bullish Signal Line Cross | Bullish | 0.00% |
| Mar 15 | 180 Bullish Setup | Bullish Swing Setup | 0.00% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-14
- Sector: Healthcare
- Industry: Pharmaceuticals
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
Medicine Chemistry Health Biopharmaceutical Cardiovascular Disease Lipid Cardiovascular Disorders Dietary Management Fatty Acids Hypertriglyceridemia Omega 3 Fatty Acid
Medicine Chemistry Health Biopharmaceutical Cardiovascular Disease Lipid Cardiovascular Disorders Dietary Management Fatty Acids Hypertriglyceridemia Omega 3 Fatty Acid
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ACST news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 1.8 |
| 52 Week Low | 0.43 |
| Average Volume | 349,241 |
| 200-Day Moving Average | 0.8117 |
| 50-Day Moving Average | 1.0338 |
| 20-Day Moving Average | 1.0465 |
| 10-Day Moving Average | 1.049 |
| Average True Range | 0.0568 |
| ADX | 13.84 |
| +DI | 14.1977 |
| -DI | 11.4437 |
| Chandelier Exit (Long, 3 ATRs ) | 0.9496 |
| Chandelier Exit (Short, 3 ATRs ) | 1.0639999999999999 |
| Upper Bollinger Band | 1.129 |
| Lower Bollinger Band | 0.964 |
| Percent B (%b) | 0.64 |
| BandWidth | 15.766842 |
| MACD Line | 0.0186 |
| MACD Signal Line | 0.0185 |
| MACD Histogram | 0.0001 |
| Fundamentals | Value |
|---|---|
| Market Cap | 15.74 Million |
| Num Shares | 14.7 Million |
| EPS | -0.77 |
| Price-to-Earnings (P/E) Ratio | -1.39 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 1.22 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.12 | ||||
| Resistance 3 (R3) | 1.11 | 1.10 | 1.11 | ||
| Resistance 2 (R2) | 1.10 | 1.09 | 1.10 | 1.10 | |
| Resistance 1 (R1) | 1.08 | 1.08 | 1.09 | 1.09 | 1.10 |
| Pivot Point | 1.07 | 1.07 | 1.07 | 1.07 | 1.07 |
| Support 1 (S1) | 1.05 | 1.06 | 1.06 | 1.06 | 1.04 |
| Support 2 (S2) | 1.04 | 1.05 | 1.04 | 1.04 | |
| Support 3 (S3) | 1.02 | 1.04 | 1.03 | ||
| Support 4 (S4) | 1.03 |
